Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study

Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticaria. A randomized, exploratory phase 2 study evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmes, Jarrod P., Peguero, Julio A., Garland, R. Campbell, North, Janine, Young, Stacia, Brent, Lonnie D., Joseph-Ridge, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health, Inc. 2021
Materias:
Features
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565502/
https://www.ncbi.nlm.nih.gov/pubmed/34555839
http://dx.doi.org/10.1097/NAN.0000000000000444
Descripción
Sumario:Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticaria. A randomized, exploratory phase 2 study evaluated intravenous (IV) cetirizine 10 mg versus IV diphenhydramine 50 mg as pretreatment in patients receiving an anti-CD20 agent or paclitaxel. In the overall population (N = 34) and an elderly subgroup (n = 21), IV cetirizine was as effective as IV diphenhydramine in preventing infusion reactions (primary outcome) and associated with less sedation at all time points, a shorter infusion center stay, and fewer treatment-related adverse events.

Ejemplares similares